oncolog
patient
suscept
perhap
less
like
undergo
sever
infectionrel
complic
due
fewer
cytokin
storm
consequ
associ
immunodefici
pdf
file
articl
undergon
enhanc
accept
addit
cover
page
metadata
format
readabl
yet
definit
version
record
version
undergo
addit
copyedit
typeset
review
publish
final
form
provid
version
give
earli
visibl
articl
pleas
note
product
process
error
may
discov
could
affect
content
legal
disclaim
appli
journal
pertain
oncolog
patient
suscept
perhap
less
like
undergo
sever
infectionrel
complic
due
fewer
cytokin
storm
consequ
associ
immunodefici
author
sara
cherri
silvia
noventa
certainli
conclud
cancer
consid
neg
prognost
factor
complic
exitu
case
infect
know
cytokin
cascad
probabl
respons
acut
respiratori
complic
patient
develop
sever
infect
assumpt
base
ongo
trial
immunosuppress
drug
select
cytokin
inhibitor
drug
molecular
target
janu
kinas
jak
inhibitor
hand
know
complex
tumor
immunolog
profil
defin
immunoedit
cancer
immunoedit
process
immun
system
limit
promot
tumor
develop
three
stage
call
elimin
balanc
escap
stage
tumor
chang
immunogen
acquir
immunosuppress
mechan
allow
diseas
progress
mani
studi
shown
sever
chemotherapi
regimen
lead
longterm
chang
immunolog
paramet
particular
deplet
lymphocyt
popul
add
cancer
patient
present
lymphopenia
regardless
ongo
treatment
consider
clinic
evid
base
observ
outcom
patient
posit
lead
us
wonder
lymphopen
statu
patient
ongo
chemotherapi
treatment
somehow
increas
suscept
infect
reduc
probabl
respiratori
complic
mayb
due
lack
adequ
lymphocyt
respons
consequ
insuffici
cytokin
cascad
studi
base
larger
oncolog
popul
provid
accur
answer
medic
hypothes
left
extend
inflammatori
involv
immunocompet
host
follow
huge
cytokin
respons
macrophag
inflammatori
protein
interleukin
il
monocyt
chemoattract
protein
granulocytecoloni
stimul
factor
induc
protein
nd
tumour
necrosi
right
oncolog
patient
undergo
immunosuppress
chemotherapi
treatment
develop
less
extens
pneumonia
uncompl
cours
due
insuffici
cytokin
respons
alter
lymphocyt
profil
none
